A powerful approach
We are leveraging the genetic principle of synthetic lethality and the power of our state-of-the-art CRISPR-based target discovery engine to discover and validate multiple novel targets each year. Our growing pipeline consists of programs for genetically defined subsets of cancers with limited treatment options.
Partnerships
Our global strategic collaboration with Gilead Sciences is focused on the discovery, development and commercialization of a pipeline of innovative targeted immune evasion therapies for patients with cancer. We are responsible for discovering and validating targets and for advancing select programs through clinical proof-of-concept. Gilead has options to worldwide rights on up to 15 of those targets. We retain the option to co-develop and co-promote the lead products for up to five of those programs in the U.S. with Gilead.
The collaboration, which was originally signed in 2018 and expanded in 2020, does not include our three lead programs. We retain all rights to those programs, along with the right to targets we have identified outside of the immune evasion space. We are committed to advancing the programs in our wholly owned pipeline into the clinic and beyond, as part of our mission to deliver the next generation of transformational targeted therapies to patients in need.
The Gilead logo is a trademark of Gilead Sciences, Inc.
We aim to become a fully-integrated biotechnology company bringing transformative medicines to people with cancer. We believe strategic collaborations with pharma and other biotech companies can help us achieve this goal and deliver more novel cancer drug targets and medicines to patients. Please reach out if you are interested in exploring ways to work together: bd@tangotx.com.
